Imlifidase Inhibits HLA Antibody-Mediated NK Cell Activation and Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) In Vitro.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important pathway responsible for antibody-mediated rejection (AMR). Imlifidase (IdeS) cleaves human IgG into F(ab')2 and Fc fragments, potentially inhibiting ADCC. Here we examined the effect of imlifidase on allo-antibody-mediated NK cell activation (Allo-CFC) and ADCC in vitro. For Allo-CFC, normal whole blood was incubated with third-party peripheral blood mononuclear cells (PBMCs) pretreated with anti-HLA antibody positive (HS) or negative (NC) sera to measure IFNγ+ NK cell%. For ADCC, normal PBMCs were incubated with Farage B cells (FB) with HS or NC sera to measure 7-AAD+ lysed FB cell%. To assess the effect of imlifidase on these assays, serum-treated PBMCs (Allo-CFC-1) and serum used for PBMC pretreatment (Allo-CFC-2) in Allo-CFC, and serum used for ADCC were preincubated with imlifidase. Sera from imlifidase-treated patients were also tested for Allo-CFC (Allo-CFC-3). IFNγ+ NK cell% were significantly elevated in HS vs. NC sera in Allo-CFC-1 (10 ± 3% vs. 2 ± 1%, p=0.001), Allo-CFC-2 (20 ± 10% vs. 4 ± 2%, p=0.01) and 7AAD+ FB cell% (11 ± 3% vs. 4 ± 2%, p=0.02) in ADCC. These were significantly reduced by imlifidase treatment. Patient sera with significantly reduced anti-HLA antibody levels at 1 day postimlifidase lost the capacity to activate NK cells in Allo-CFC-3, but those at 1-3 months postimlifidase regained the capacity. Imlifidase inhibited NK cell activation and ADCC in vitro and in treated patients. These results and reported inhibition of complement activating anti-HLA antibodies by imlifidase suggest its possible role in treatment of AMR.